BrigatinibMeSH Supplementary Concept

https://ansm.sante.fr/tableau-marr/brigatinib
2024
false
false
false
France
French
risk management
brigatinib
patients guideline
patient education handout
drug information
Pneumonitis
Interstitial lung disease (disorder)
brigatinib
administration, oral
antineoplastic agents
protein kinase inhibitors

---
https://www.has-sante.fr/jcms/p_3201262/fr/alunbrig
2020
false
false
false
France
treatment outcome
insurance, health, reimbursement
brigatinib
carcinoma, non-small-cell lung
ALK Inhibitor
Anaplastic Lymphoma Kinase
antineoplastic agents
protein kinase inhibitors
adult
brigatinib
Tyrosine Kinase Inhibitors
evaluation of the transparency committee
brigatinib
organophosphorus compounds
pyrimidines

---
https://www.has-sante.fr/jcms/p_3118131/fr/alunbrig
2019
false
false
false
France
brigatinib
brigatinib
adult
treatment outcome
insurance, health, reimbursement
antineoplastic agents
carcinoma, non-small-cell lung
administration, oral
bronchial neoplasms
evaluation of the transparency committee
brigatinib
organophosphorus compounds
pyrimidines

---
https://www.ema.europa.eu/en/medicines/human/EPAR/alunbrig
2018
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
brigatinib
brigatinib
brigatinib
adult
carcinoma, non-small-cell lung
carcinoma, non-small-cell lung
mutation
administration, oral
product surveillance, postmarketing
aged
drug interactions
pregnancy
breast feeding
antineoplastic agents
antineoplastic agents
protein kinase inhibitors
protein kinase inhibitors
drug evaluation, preclinical
Tyrosine Kinase Inhibitors
organophosphorus compounds
pyrimidines
organophosphorus compounds
pyrimidines
receptor Protein-Tyrosine kinases
Anaplastic Lymphoma Kinase

---